WHO ICTRP trial
Guanabenz in VWM
NL-OMON24121 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON24121 |
|---|---|
| Public title | Guanabenz in VWM |
| Scientific title | A study to explore the safety, tolerability, pharmacokinetic profile, and potential efficacy of Guanabenz in patients with early childhood onset Vanishing White Matter (VWM) |
| Primary sponsor | Amsterdam University Medical Centers, location VUmc, De Boelelaan 1117, 1081HV Amsterdam |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | Vanishing White Matter (VWM) Childhood ataxia with central nervous system hypomyelination (CACH) |
| Interventions | Guanabenz [(2,6-dichlorobenzylidene)amino] guanidine monoacetate |
| Registration date | Sep 16, 2018 |
| Target size | 30 |
| Secondary IDs | NL7260;NTR7482;2017-001438-25 : EudraCT |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: